Acrivon Therapeutics shares surge 11.18% after-hours as Zacks upgrades to Buy citing improved earnings outlook.

Acrivon Therapeutics (ACRV) surged 11.18% in after-hours trading following an upgrade to Zacks Rank #2 (Buy), driven by upward revisions in earnings estimates. The Zacks system, which prioritizes quantifiable earnings forecast improvements, highlighted growing institutional and investor optimism about the company’s financial outlook. Concurrently, analysts at JonesTrading and H.C. Wainwright reiterated Buy ratings, while advancements in Acrivon’s pipeline—including Fast Track designations for ACR-368 in ovarian and endometrial cancers—reinforced its therapeutic potential. These developments, coupled with positive estimate revisions, fueled immediate buying pressure, aligning with empirical trends linking earnings revisions to short-term stock performance. The upgrade and pipeline progress collectively positioned Acrivon as a top 20% performer in Zacks-covered stocks.